SurModics (SRDX) Reports In-Line Q4 EPS, Revenues Beat; Offers FY20 EPS/Revenue Guidance Below Consensus
- Stocks and yen struggle as tech troubles weigh
- Meta shares dip on softer Q2 revenue guidance, elevated AI spending plans
- Oil steady as US demand concerns balance Middle East conflict risks
- Yen at multi-decade lows, dollar drops before US data
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Hasbro (HAS) brand strength sees earnings top expectations
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Crude Inventory Declined 6.4 Million Barrels Last Week
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
Surmodics Reports Fourth Quarter Fiscal 2019 Results and Issues Fiscal 2020 Revenue and EPS Guidance
October 31, 2019 4:05 PM EDTEDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2019 fourth quarter ended September 30, 2019, and provided its financial outlook for fiscal 2020.
Summary of Fourth Quarter and Recent Highlights
Revenue of $30.8 million, an increase of 33.8% year-over-year GAAP EPS of $0.26, non-GAAP EPS of $0.37 Completed enrollment in TRANSCEND pivotal clinical trial for SurVeil drug-coated balloon (DCB) Completed enrollment in first in-human study for Avess arteriovenous (AV) access... More